Next Century Growth Investors LLC Invests $6.53 Million in Phathom Pharmaceuticals, Inc. $PHAT

Next Century Growth Investors LLC acquired a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 393,774 shares of the company’s stock, valued at approximately $6,533,000. Next Century Growth Investors LLC owned 0.55% of Phathom Pharmaceuticals at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth about $1,908,000. Hussman Strategic Advisors Inc. purchased a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth about $2,439,000. GW&K Investment Management LLC raised its holdings in shares of Phathom Pharmaceuticals by 9.1% in the 3rd quarter. GW&K Investment Management LLC now owns 1,144,330 shares of the company’s stock worth $13,469,000 after purchasing an additional 95,858 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Phathom Pharmaceuticals in the 3rd quarter worth about $827,000. Finally, Stratos Wealth Partners LTD. purchased a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth about $834,000. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Stock Performance

PHAT stock opened at $10.37 on Monday. Phathom Pharmaceuticals, Inc. has a 1 year low of $7.61 and a 1 year high of $18.31. The firm has a market cap of $827.11 million, a P/E ratio of -4.89 and a beta of 0.51. The stock has a 50-day simple moving average of $11.52 and a 200-day simple moving average of $12.86.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Barclays upgraded Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $16.00 to $18.00 in a research note on Friday, March 27th. Guggenheim increased their target price on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Stifel Nicolaus set a $28.00 target price on Phathom Pharmaceuticals in a research note on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Phathom Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $24.50.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical?stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium?competitive acid blocker (P-CAB) licensed for use in the United States.